Abstract-Nicotine (0.5 and 1.0 mg/kg) administered subcutaneously to mice decreased the ambulatory activity recorded by an ambulo-meter in a dose-dependent manner from 5 to 60 min after the administration, and the higher dose (1.0 mg/kg) caused a long-lasting ataxia. To be noted was the initial increment of ambulation which usually preceded the ataxia-inducing effect with every dose of nicotine, and the lowest dose (0.10 mg/kg) employed herein induced only the increasing effect on ambulation recorded for the first 20 min after its administration. The ataxia inducing effect of nicotine (1.0 mg/kg) was attenuated by the pretreatment with mecamylamine (0.4-2.0 mg/kg) in a dose-dependent manner, though the at tenuating effect waned at a higher dose (4.0 mg/kg). In contrast, pretreatment with either hexamethonium (2.5 and 5.0 mg/kg) or atropine (1.0, 2.5 and 5.0 mg/ kg) did not affect the ataxia-inducing effect of nicotine. Atropine when adminis tered alone was found to markedly increase the ambulatory activity at the doses used for the pretreatment. Measurement of the time-dependent change of[3H]-nicotine level in brain tissue after its subcutaneous injection revealed that there is a good correlation between the brain levels of the alkaloid and the intensity of its ataxic effect rather than the initial increasing effect on ambulation. The results obtained herein suggest that nicotine exerts its ataxic effect centrally, but the site and type of the receptor stimulated by nicotine remains to be identified.
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There have been many studies on the effects of nicotine on the spontaneous motor activity of drug-naive or drug-tolerant mice and rats (1) (2) (3) (4) .
The commonly observed effect on drug-naive animals has been inhi bition of the spontaneous motor activity, which developed in a dose-dependent manner, and high dose levels led to a typical ataxia. In contrast, the studies on drug tolerant animals have shown that the drug acted as a stimulant on the spontaneous activity (3). Rosecrans and Schechter (5) attempted to correlate the behavioral effects of the alkaloid with the brain levels of nicotine. Clarke and Kumar (3) reported that mecamylamine, a specific antagonist of nicotine in the nicotinic receptor of autonomic ganglion, was able to prevent not only the initial inhibitory effect on the spontaneous motor activity of drug-naive rats but also the stimulating action in the tolerant animals (3). These observations suggest that nicotine exerts its seemingly diverse effects by directly acting on nicotinic acetylcholine receptor within the brain tissues. However, there are some evidences to indicate the possibility that the muscarinic receptor is also involved in the behavioral effects of nicotine. Ebenezer (6) observed that atropine pretreatment is able to reverse the initial inhibitory effect of nicotine on the spontaneous motor activity of drug-naive rats.
In the experiments reported herein, we attempted to investigate how the behavioral effect of nicotine in drug-naive mice would be affected by the pretreatment with mecamyla mine, hexamethonium and atropine and to correlate the time course of the behavioral effect with the rise and fall-pattern of the brain levels of the drug.
Materials and Methods

Animals
Male ddY mice aged 4 weeks (Kiwa Experi mental Animals Laboratories, Wakayama, Japan) weighing from 18 to 23 g were pur chased. Groups of 10 mice were housed in aluminium cages with dimensions of 22 (W) x 32 (D) x 10 (H) cm, and the animals were given a solid diet (MF: Oriental Yeast Co., Tokyo) and tap water ad libitum under a 12 hr light/dark cycle with dawn and dusk (each over 2 hr) for 3 weeks. The room temperature was kept at 23±2°C, and the humidity was 60±10%. All animals were 7 weeks old and weighed from 28 to 33 g at the start of the experiment. Drugs (-)-Nicotine (Maruwaka Chem., Osaka), mecamylamine hydrochloride (Sigma), hex amethonium bromide (Sigma), atropine sulfate monohydrate (Wako Chem., Osaka), (-)-[N-methyl-3H] nicotine (60 Ci/mmol, Amersham, Japan) and saline (Otsuka, Tokyo) were used. The drugs were dissolved in saline and injected subcutaneously in a volume of 0.1 ml/10 g. Doses were expressed in terms of the free base of the drug. Apparatus
The ambulatory activity was measured with an ambulo-meter (AMB: O'Hara & Co., Ltd., Tokyo). The principles of the device and the method for measurement of ambulatory activity in mice have been reported by Hirabayashi et al. (7) . Briefly, each tilting of the mouse is recorded through a microswitch attached to the cage. The apparatuses were set up in the animal room, and the cumulative activity counts during every 5 min segment was printed on paper with an electromag netic counter (TIDP: O'Hara & Co., Ltd., Tokyo) in the adjacent room. All the experi ments were conducted between 9:30 and 13:00. Procedure Studies of behavior All mice were naive to drugs and had no previous experience of the apparatus before the start of the experiment. Experiment 1: Effects of different doses of nicotine on the ambulatory activity of mice: Each mouse was given an injection of nicotine (0.1, 0.5 and 1.0 mg/kg) and then put into each ambulo-cage. The activity counts were recorded during a 180 min period. The control group was injected with saline. After placing each mouse in an aluminium cage (the same size as the home cage but a different one) for 20 min, each mouse was injected with nicotine (1.0 mg/kg) or saline and then transferred into an ambulo cage. The ambulatory activity counts were recorded for a total of 180 min, but for the comparison of the activity between mice, the counts recorded for a 15 min period from 10 to 25 min after nicotine or saline injection were employed, because the ataxia-inducing effect of nicotine was found to reach a plateau. Measurement of nicotine levels in the brain The nicotine levels in the brain were measured by the method of Martin et al. (8) . Mice were decapitated at 5, 10, 15, 20, 60 and 120 min after injection of 1 mg/kg of (-) [3H]nicotine (100 eeCi/mg nicotine), and each brain was homogenized in 5 ml of 0.05 N hydrochloric acid with 10 strokes of a glass homogenizer fitted with a teflon pestle. Ex traction was performed by the method of Huker et al. (9) . The brain homogenate was made basic with 3 drops of concentrated am monium hydroxide and 1.0 ml of 40% K3PO4 (W/V), to which (-)-nicotine (1 mg/200 ,al) as a carrier was added. After centrifuga tion at 1970xg for 5 min, 2 ml of the hexane layer was removed, and the radioactivity was counted by liquid scintillation spectrometry (Packard Model 3255). Statistical analysis Statistical analysis was carried out by Student's t-test.
Results
1)
Effects of different doses of nicotine on the ambulatory activity of mice: Figure 1 A shows the time course of the ambulatory ac tivity recorded for each 20 min period, for a total of 180 min, after placing the animal in the ambulatory cage and the effects of dif ferent doses of nicotine. In the saline-treated control group, the activity was the highest in the first period and thereafter gradually de creased.
Nicotine (1.0 mg/kg) persistently depressed the activity from the first period to the third according to the data recorded in this manner. Even in the lower dose (0.5 mg/kg), the drug tended to depress the acti vity for at least 40 min. The lowest dose (0.1 mg/kg) showed no depressive effect through out the experiment; and rather, in the first period, the drug was found to significantly stimulate the ambulatory activity.
The biphasic pattern of effects of nicotine on the ambulatory activity of mice became more prominant when the initial two 20 min periods were divided into eight 5 min periods. As shown in Fig. 1 B, nicotine in all doses employed herein first increased the activity, and then the ataxic phase of effects of the drug developed, if any, as noted with the high doses of 0.5 or 1.0 mg/kg. The latter phase of the effect was apparently dose-dependent, and the highest dose (1.0 mg/kg) elicited a marked and long-lasting ataxia as seen in Fig. 1 A. 2) Effects of pretreatment with mecamyla mine, hexamethonium and atropine on the ataxia-inducing effect of nicotine (1.0 mg/kg) in mice: In mice pretreated with varying doses of mecamylamine, the ataxia inducing effect of nicotine was found to be effectively antagonized by the nicotinic an tagonist in a dose range of 0.4-2.0 mg/kg. The antagonism developed in a dose dependent manner. In a higher dose (4.0 mg/kg), however, the antagonist exhibited its intrinsic inhibitory effect on the ambulatory activity, and no antagonism was discernible (Fig. 2) . 
Discussion
The present study reveals that high doses of nicotine (0.5 and 1.0 mg/kg) administered subcutaneously to mice decreased the ambulatory activity in a dose-dependent manner from 5 to 60 min after the adminis tration, and the higher dose (1.0 mg/kg) caused a long-lasting ataxia. These findings are consistent with the majority of previous studies. Morrison and Armitage (10) reported that high doses of nicotine (0.4 and 0.8 mg/kg) administered subcutaneously to mice strongly decreased the spontaneous motor activity (in light beam boxes), leading to no motor activity for the first 10 to 15 min, and the effect lasted at least for the first 60 min. In contrast, a low dose (0.1 mg/kg) of nico tine failed to decrease the ambulatory activity, but rather increased the activity during the first 20 min after the administration. The present study shows that there is a good correlation between the brain level of [3H]nicotine and the intensity of its ataxia inducing effect. Similar results have been re ported by Rosecrans and Schechter (5) for rats and Mansner (11) for mice, although the brain level after the peak in rats waned more slowly than that in mice. The results taken together suggest that acute-tolerance would not develop to the ataxia-inducing effect of nicotine, at least, within 60 min after the ad ministration.
It is well-known that the quaternary amines such as hexamethonium, generally would not penetrate easily the blood-brain barrier (12) . Thus, a possible conclusion would be that nicotine was able to be antagonized beyond the barrier by mecamylamine which could more readily penetrate the barrier than hexamethonium.
However, it has been re ported that the nicotinic antagonists (hex amethonium, decamethonium and mecamyla mine) are poor inhibitors of binding of [3H] nicotine and a-[125 I]bungarotoxin to the brain membrane fraction (13, 14) . The next step of our study should be identification of the site and type of the receptor at which the antagonism between nicotine and mecamyla mine would take place, because many of the behavioral effects of nicotine were in fact blocked by this antagonist, possibly involving the cholinergic receptor in the brain (15) . Ebenzer (6) reported that atropine pre treatment effectively blocks the depressant effect of nicotine on the spontaneous motor activity of drug-naive rats. In the present study, however, atropine failed to affect the ataxic effect of nicotine (1.0 mg/kg) in mice, while the pretreatment alone was found to markedly increase the ambulatory activity. On the other hand, our observations of the latter increasing effect appear to be in accord with the results reported by Kuribara and Tadokoro (16) . They reported that scopola mine administered subcutaneously to mice increased the ambulatory activity, suggesting that the increase is caused by the central muscarinic blockade. A similar mechanism would be functioning for the intrinsic action of atropine observed herein.
In conclusion, the results obtained herein suggest that nicotine exerts its ataxic effect centrally and possibly by directly acting on the nicotinic acetylcholine receptor, but more detailed studies are needed in order to identify the site and type of the receptor that is affected by nicotine to produce the behavioral effect.
